Clinical Trial Update: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection [Phase 3]

View source ↗

Summary

Phase 3 study evaluating simeprevir (TMC435) in combination with pegylated interferon alfa-2a and ribavirin for chronic hepatitis C infection; the trial has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)
• Simeprevir (simeprevir)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Hepatitis C, Chronic, Infection | Phase 3 | Status: COMPLETED